Health Care · Pharmaceuticals

JNJ Johnson & Johnson

$271.33 on 2026-10-28 · $653.1B · +46.7%

Johnson & Johnson is a mega cap Health Care company in Pharmaceuticals. At $271.33 a share the market values it at $653.1 billion, up 47% over the past year.

Does JNJ pass the rule?

Members see the model's value and upside, the six tests, the quality score and which funds are buying or selling.

Become a member$11.99/week · $24.99/month · $199.99/year

+ Model value & upside+ The six tests+ 13F fund flows

How the rule judges a company

Is JNJ undervalued? Six plain tests

The rule asks what Buffett-style investors ask, using only Johnson & Johnson’s own SEC filings: is it worth more than its price (upside of 20% or more to model value), is it a good business (a quality score of 0.5 or more), does it really make money (profits and positive cash earnings), and can it carry its debt (net debt under 3.5× operating income)?

It also skips cyclicals at peak margins, where today’s profits flatter the price. Read the method in plain English, exactly how each number is calculated, or why a margin of safety matters.

Health Care

Other Health Care companies

All Health Care →

Who owns JNJ? Funds managing over $100M report their US holdings every quarter on Form 13F. See the latest 13F filings as they land on SEC EDGAR.

Research only, not investment advice. Figures come from JNJ’s SEC filings (trailing twelve months to 2026-09-27) and daily closes.